Fig. 3

Antitumor activity of osimertinib and bevacizumab in the EGFR-mutant LM model A. Representative images of luciferin signals at weeks 0 and 2, significantly lower luciferin signals were detected in osimertinib and bevacizumab-treated animals compared with other groups after 2 weeks treatments. B The quantification of luciferin signals of (A) (p < 0.05). C Body weight changes in four groups of LM xenografts model (n = 6). D IVIS imaging of the osimertinib group and osimertinib plus bevacizumab group after 3 weeks treatments. E The quantification of luciferin signals of (D). F Survival curves of four groups (n = 6, log-rank test, **** means p < 0.0001). G The H&E staining for the four groups